Physiologically based pharmacokinetic (PBPK) modelling tools: how to fit with our needs?

In 2005, a survey compared a number of commercial PBPK software available at the time, mainly focusing on ‘ready to use’ modelling tools. Since then, these tools and software have been further developed and improved to allow modellers to perform WB‐PBPK modelling including ADME processes at a high level of sophistication. This review presents a comparison of the features, values and limitations of both the ‘ready to use’ software and of the traditional user customizable software that are frequently used for the building and use of PBPK models, as well as the challenges associated with the various modelling approaches regarding their current and future use. PBPK models continue to be used more and more frequently during the drug development process since they represent a quantitative, physiologically realistic platform with which to simulate and predict the impact of various potential scenarios on the pharmacokinetics and pharmacodynamics of drugs. The ‘ready to use’ PBPK software has been a major factor in the increasing use of PBPK modelling in the pharmaceutical industry, opening up the PBPK approach to a broader range of users. The challenge is now to educate and to train scientists and modellers to ensure their appropriate understanding of the assumptions and the limitations linked both to the physiological framework of the ‘virtual body’ and to the scaling methodology from in vitro to in vivo (IVIVE). Copyright © 2012 John Wiley & Sons, Ltd.

[1]  Hartmut Derendorf,et al.  Pharmacokinetic/Pharmacodynamic Modeling in Drug Research and Development , 2000, Journal of clinical pharmacology.

[2]  M. Niemi,et al.  Membrane transporters in drug development , 2010, Nature Reviews Drug Discovery.

[3]  Walter Schmitt,et al.  A physiological model for the estimation of the fraction dose absorbed in humans. , 2004, Journal of medicinal chemistry.

[4]  Stephanie Läer,et al.  Physiologically Based Pharmacokinetic Modeling: Methodology, Applications, and Limitations with a Focus on Its Role in Pediatric Drug Development , 2011, Journal of biomedicine & biotechnology.

[5]  Sarah Whalley,et al.  Predictions of Metabolic Drug-Drug Interactions Using Physiologically Based Modelling , 2010, Clinical pharmacokinetics.

[6]  Kazuya Maeda,et al.  Physiologically Based Pharmacokinetic Modeling to Predict Transporter-Mediated Clearance and Distribution of Pravastatin in Humans , 2009, Journal of Pharmacology and Experimental Therapeutics.

[7]  Tim Morris,et al.  Physiological Parameters in Laboratory Animals and Humans , 1993, Pharmaceutical Research.

[8]  Jianghong Fan,et al.  PBPK modeling of intestinal and liver enzymes and transporters in drug absorption and sequential metabolism. , 2010, Current drug metabolism.

[9]  M Danhof,et al.  Relevance of the Application of Pharmacokinetic-Pharmacodynamic Modelling Concepts in Drug Development , 1997, Clinical pharmacokinetics.

[10]  M. Delp,et al.  Physiological Parameter Values for Physiologically Based Pharmacokinetic Models , 1997, Toxicology and industrial health.

[11]  C C Peck,et al.  Optimizing the science of drug development: opportunities for better candidate selection and accelerated evaluation in humans. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[12]  Jasper Dingemanse,et al.  Integrated Pharmacokinetics and Pharmacodynamics in Drug Development , 2007, Clinical pharmacokinetics.

[13]  Walter Schmitt,et al.  Physiology-based pharmacokinetic modeling: ready to be used. , 2004, Drug discovery today. Technologies.

[14]  Walter Schmitt,et al.  PK-Sim®: a physiologically based pharmacokinetic ‘whole-body’ model , 2003 .

[15]  U. Fagerholm.  Prediction of human pharmacokinetics —gastrointestinal absorption , 2007, The Journal of pharmacy and pharmacology.

[16]  M. Jamei,et al.  A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: A tale of 'bottom-up' vs 'top-down' recognition of covariates. , 2009, Drug metabolism and pharmacokinetics.

[17]  Stefan S De Buck,et al.  Physiologically based approaches towards the prediction of pharmacokinetics: in vitro–in vivo extrapolation , 2007, Expert opinion on drug metabolism & toxicology.

[18]  Dominique Tytgat,et al.  Physiologically based pharmacokinetics (PBPK) , 2009, Drug metabolism reviews.

[19]  A. Rostami-Hodjegan,et al.  'In silico' simulations to assess the 'in vivo' consequences of 'in vitro' metabolic drug-drug interactions. , 2004, Drug discovery today. Technologies.

[20]  Malcolm Rowland,et al.  Physiologically based pharmacokinetics in Drug Development and Regulatory Science: A workshop report (Georgetown University, Washington, DC, May 29–30, 2002) , 2004, AAPS PharmSci.

[21]  O. Blin,et al.  [Role of pharmacokinetic-pharmacodynamic relationships in drug development]. , 2002, Therapie.

[22]  Malcolm Rowland,et al.  Optimizing the Science of Drug Development: Opportunities for Better Candidate Selection and Accelerated Evaluation in Humans , 2004, Pharmaceutical Research.

[23]  Ivan Nestorov,et al.  Whole-body physiologically based pharmacokinetic models , 2007, Expert opinion on drug metabolism & toxicology.

[24]  T. Lavé,et al.  A Novel Strategy for Physiologically Based Predictions of Human Pharmacokinetics , 2006, Clinical pharmacokinetics.

[25]  M. Rowland,et al.  Hepatic clearance of drugs. II. Experimental evidence for acceptance of the “well-stirred” model over the “parallel tube” model using lidocaine in the perfused rat liverin situ preparation , 1977, Journal of Pharmacokinetics and Biopharmaceutics.

[26]  S. Paine,et al.  The Impact of Hepatic Uptake on the Pharmacokinetics of Organic Anions , 2011, Drug Metabolism and Disposition.

[27]  L Zhang,et al.  Applications of Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation During Regulatory Review , 2011, Clinical pharmacology and therapeutics.

[28]  Malcolm Rowland,et al.  PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approach. , 2011, Journal of pharmaceutical sciences.

[29]  K. Pang,et al.  Physiological Modeling to Understand the Impact of Enzymes and Transporters on Drug and Metabolite Data and Bioavailability Estimates , 2010, Pharmaceutical Research.

[30]  Malcolm Rowland,et al.  PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: comparative assessement of prediction methods of human clearance. , 2011, Journal of pharmaceutical sciences.

[31]  G. Hempel,et al.  Physiologically based pharmacokinetic modelling of high- and low-dose etoposide: from adults to children , 2012, Cancer Chemotherapy and Pharmacology.

[32]  Kiyomi Ito,et al.  Comparison of the Use of Liver Models for Predicting Drug Clearance Using in Vitro Kinetic Data from Hepatic Microsomes and Isolated Hepatocytes , 2004, Pharmaceutical Research.

[33]  Thierry Lavé,et al.  PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 1: goals, properties of the PhRMA dataset, and comparison with literature datasets. , 2011, Journal of pharmaceutical sciences.

[34]  R. Riley,et al.  Functional Consequences of Active Hepatic Uptake on Cytochrome P450 Inhibition in Rat and Human Hepatocytes , 2008, Drug Metabolism and Disposition.

[35]  Yuichi Sugiyama,et al.  Application of physiologically based pharmacokinetic modeling and clearance concept to drugs showing transporter-mediated distribution and clearance in humans , 2010, Journal of Pharmacokinetics and Pharmacodynamics.

[36]  U. Fagerholm.  Prediction of human pharmacokinetics—evaluation of methods for prediction of hepatic metabolic clearance , 2007, The Journal of pharmacy and pharmacology.

[37]  U. Fagerholm.  Prediction of human pharmacokinetics — renal metabolic and excretion clearance , 2007, The Journal of pharmacy and pharmacology.

[38]  U. Fagerholm.  Prediction of human pharmacokinetics—gut‐wall metabolism , 2007, The Journal of pharmacy and pharmacology.

[39]  Sebastian Polak,et al.  Population-Based Mechanistic Prediction of Oral Drug Absorption , 2009, The AAPS Journal.

[40]  G. Tucker,et al.  A Semi-Mechanistic Model to Predict the Effects of Liver Cirrhosis on Drug Clearance , 2010, Clinical pharmacokinetics.

[41]  Rhys D O Jones,et al.  PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 4: prediction of plasma concentration-time profiles in human from in vivo preclinical data by using the Wajima approach. , 2011, Journal of pharmaceutical sciences.

[42]  B Agoram,et al.  Predicting the impact of physiological and biochemical processes on oral drug bioavailability. , 2001, Advanced drug delivery reviews.

[43]  Martin Kuentz,et al.  A strategy for preclinical formulation development using GastroPlus as pharmacokinetic simulation tool and a statistical screening design applied to a dog study. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[44]  B. Walther,et al.  Pharmacokinetic predictions in children by using the physiologically based pharmacokinetic modelling , 2008, Fundamental & clinical pharmacology.

[45]  U. Fagerholm,et al.  Prediction of human pharmacokinetics – evaluation of methods for prediction of volume of distribution , 2007, The Journal of pharmacy and pharmacology.

[46]  Y. Sugiyama,et al.  Model Analysis of the Concentration-Dependent Permeability of P-gp Substrates , 2010, Pharmaceutical Research.

[47]  Peter J H Webborn,et al.  Prediction of the Pharmacokinetics of Atorvastatin, Cerivastatin, and Indomethacin Using Kinetic Models Applied to Isolated Rat Hepatocytes , 2008, Drug Metabolism and Disposition.

[48]  Stefan Willmann,et al.  Physiology-based pharmacokinetic modeling: ready to be used. , 2004, Drug discovery today. Technologies.

[49]  Malcolm Rowland,et al.  PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 2: comparative assessment of prediction methods of human volume of distribution. , 2011, Journal of pharmaceutical sciences.

[50]  Malcolm Rowland,et al.  Physiologically-based pharmacokinetics in drug development and regulatory science. , 2011, Annual review of pharmacology and toxicology.

[51]  Patrizia Crivori,et al.  Evaluation of a basic physiologically based pharmacokinetic model for simulating the first-time-in-animal study. , 2007, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[52]  Leslie Z Benet,et al.  Lead PK commentary: predicting human pharmacokinetics. , 2011, Journal of pharmaceutical sciences.

[53]  Melvin E. Andersen,et al.  Introduction: A Historical Perspective of the Development and Applications of PBPK Models , 2005 .

[54]  Neil Parrott,et al.  Applications of physiologically based absorption models in drug discovery and development. , 2008, Molecular pharmaceutics.

[55]  K. Sandy Pang,et al.  Physiologically-based pharmacokinetic modeling for absorption, transport, metabolism and excretion , 2010, Journal of Pharmacokinetics and Pharmacodynamics.

[56]  Masoud Jamei,et al.  Physiologically based mechanistic modelling to predict complex drug-drug interactions involving simultaneous competitive and time-dependent enzyme inhibition by parent compound and its metabolite in both liver and gut - the effect of diltiazem on the time-course of exposure to triazolam. , 2010, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[57]  Stefan Willmann,et al.  Physiology-Based Simulations of a Pathological Condition , 2008, Clinical pharmacokinetics.

[58]  Ivan Nestorov,et al.  Whole Body Pharmacokinetic Models , 2003, Clinical pharmacokinetics.